Equity Overview
Price & Market Data
Price: $0.877
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $12,816,506
Volume: 0
Performance Metrics
1 Week: -0.17%
1 Month: -17.69%
3 Months: -1.53%
6 Months: -11.05%
1 Year: -25.08%
YTD: -7.73%
Company Details
Employees: 25
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Imunon, Inc., a clinical-stage biotechnology company, develops immunotherapies and next-generation vaccines. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.